CanSino Biologics trigger immune response: Chinese researchers


New Delhi: Chinese researchers have claimed that a potential coronavirus vaccine developed by the CanSino Biologics appeared safe and triggered an immune response.

Results from the early clinical trial suggested that the experimental COVID-19 vaccine, called Ad5-nCoV, could help train the body to recognise and resist infection by the new SARS-CoV-2 virus.

Reports said Ad5-nCoV is the first vaccine for COVID-19 to enter clinical trial in China. It uses a weakened common cold virus known as an adenovirus, which infects human cells but doesn’t cause disease.

The experimental vaccine is built upon CanSinoBIO’s adenovirus-based viral vector vaccine technology platform. Results from preclinical animal studies of the vaccine showed that ‘Ad5-nCoV’ can induce a strong immune response in animal models, demonstrating a good safety profile.

The researchers observed that three weeks after vaccinations in all three groups developed binding antibodies.

Leave A Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.